Navigation Links
Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
Date:6/17/2009

CHERRY HILL, N.J., June 17 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that it has renewed its Master Distribution Agreement with MedX, Inc., a Malvern, PA-based provider of office-based surgical and aesthetic solutions, for the distribution and sale of its Talsyn Scar Cream through physicians offices.

The renewal is for one year and provides MedX with an increased distributor margin, enabling a more aggressive and sustained marketing promotion effort. Additionally, the minimum order size has been increased to 5,000 units, from 1,000 units. Nuvilex and MedX have also agreed to new pricing for Talsyn, lowering the suggested retail price to $29.95 from $65.00. The pricing change is expected to enhance Talsyn's competitive positioning relative to other major scar treatment brands.

"Since 2006, MedX has worked diligently to establish a physician's office sales base for Talsyn," stated Martin Schmieg, Chairman and Chief Executive. "The scar treatment market is a highly competitive market. We renewed our distribution agreement with MedX in order further leverage the Talsyn franchise they have created. The higher margins for MedX and a more competitively priced product should translate to more aggressive marketing of our product, which we believe will result in increased sales of Talsyn by the fall of 2009."

About Talsyn

Talsyn-CI Scar Cream is a unique, fragrant composition that delivers lipids, peptides, and botanical extracts to the skin, including extracts from algae, rosemary, rosehip, and mango. Talsyn-Cl Scar Cream has been clinically proven to improve the appearance of keloids, surgical incisions, and scars and is composed mostly of glycine soja oil (derived from soybeans), aloe vera, and calophyllum oil. Calophyllum oil (tamanu oil), an ingredient derived from trees in the tropics, was revered by ancient Polynesian wound healers for its ability to accelerate healing and improve the appearance of scars. In addition, these all-natural emollients help to keep the skin looking healthy, vibrant, and well hydrated. Talsyn's unique combination of rich, plant-derived ingredients will not damage clothing or stain fabrics. Talsyn-CI Scar Cream is also endorsed by leading plastic and reconstructive surgeons across the US.

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

About MedX, Inc.

Based out of Malvern PA, MedX, Inc. is a premier provider of office-based surgical and aesthetic solutions. Our mission is to provide affordable access to cutting edge technology, products and services to qualified physicians and related healthcare facilities. Our combined 35+ years experience offers a truly unique consultative approach in assisting physicians. More information is available at http://www.gotMedX.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:
    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:
    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Featured in Wall Street Reporter Interview
2. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
3. Nuvilex Launches Video Marketing Campaign
4. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
5. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
6. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
7. Nuvilex, Inc. Announces Monthly Investor Conference Call
8. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
9. Nuvilex, Inc. Announces Investor Conference Call and Open House
10. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
11. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based ... industry. The organization, which plans to publish the first ANSI-approved GMP standard ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices has recently updated its ... equipment shapes for free and download shapes and stencils from http://www.VisioStencils.com. ...
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of ... protocols involve many repetitive steps and often scientists require many different versions of ... needed, and results in a lower error rate and cost saving for reagents ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology: